Country: Malaysia
Bahasa: Inggeris
Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
MONTELUKAST SODIUM
BioCare Pharmaceutical (M) Sdn. Bhd.
MONTELUKAST SODIUM
10 X 10tablet Tablets
Macleods Pharmaceuticals Limited
_ _ _ _ _Consumer Medication information Leaflet (RiMUP) _ MONTEMAC 5 (MONTELUKAST CHEWABLE TABLETS 5 MG) 1 WHAT IS IN THIS LEAFLET 1. What MONTEMAC 5 is used for r 2. How MONTEMAC 5 works 3. Before you use MONTEMAC 5 4. How to use MONTEMAC 5 5. While you are using it 6. Side effects 7. Storage and Disposal of MONTEMAC 5 8. Product Description 9. Manufacturer and Product Registration Holder 10. Date of Revision WHAT MONTEMAC 5 IS USED FOR MONTEMAC 5 is used for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. Montelukast is indicated in adults and pediatric patients 2 years of age and older for the relief of daytime and nightime symptoms of seasonal allergic rhinitis. HOW MONTEMAC 5 WORKS MONTEMAC 5 is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, MONTEMAC 5 improves asthma symptoms and helps control asthma. BEFORE YOU USE MONTEMAC 5 _When you must not take it_ Do not take Montelukast Tablet if your child is allergic (hypersensitive) to montelukast or any of the other ingredients of MONTEMAC 5. _ _ _Before you start to take it_ If your child’s asthma or breathing gets worse, tell your doctor immediately. Oral MONTEMAC 5 is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given your child. Always have your child’s inhaled rescue medicine for asthma attacks with you. It is important that your child take all asthma medications prescribed by your doctor. MONTEMAC 5 should not be used instead of other asthma medications your doctor has prescribed for your child. Any patients on anti-asthma medicines should be aware that if your child develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your child’s doctor. Your child should not take acetylsalicylic acid (aspirin Baca dokumen lengkap
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory MONTEMAC 5 MONTELUKAST CHEWABLE TABLETS 5 MG COMPOSITION Each chewable tablet contains: Montelukast Sodium USP 5.2 mg Equivalent to Montelukast…...5 mg DESCRIPTION Montelukast sodium is leukotriene receptor antagonist. Chemically, Montelukast sodium is [R-(E)]-1-[[[1-[3-[2-(7-chloro-2quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1 -methylethyl)phenyl]propyl]thio]methyl] cyclopropane acetic acid, monosodium salt. Its molecular formula is C H ClNNaO S, and molecular 35 35 3 weight is 608.18. PHARMACEUTICAL FORM Pink color, mottled, circular, biconvex, uncoated chewable tablet debossed with 'CL 56' on one side and plain on other side. PHARMACOLOGICAL CLASSIFICATION Leukotriene Receptor Antagonist PHARMACOLOGICAL ACTION: PHARMACOKINETICS ABSORPTION : Montelukast is rapidly absorbed following oral administration. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. For the 5 mg chewable tablet, the Cmax is achieved in two hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal. After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age in the fasted state, Cmax is achieved 2 hours after administration. The mean Cmax is 66% higher while mean Cmin is lower than in adults receiving a 10 mg tablet. DISTRIBUTION : Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Biotransformation Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children. Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4, and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables o Baca dokumen lengkap